Integrating Next-Generation Sequencing Into Clinical Cancer Diagnostics

Maurice Chan; Charlie W-H Lee; Mengchu Wu


Expert Rev Mol Diagn. 2013;13(7):647-650. 

In This Article

Abstract and Introduction


The advent of next-generation sequencing (NGS) has increased the throughput of DNA sequencing by >500,000-fold compared to traditional Sanger sequencing, while drastically plummeting the sequencing costs. The Human Genome Project completed a decade ago took 13 years and about US$3 billion to sequence the first human genome using shotgun method by Sanger sequencing. In contrast, by using NGS, sequencing a human diploid genome at 50–100 coverage costs about US$5000 nowadays and only takes a day or two;[102] '$1000 genome' – a goal to be attained in the near future – will be a critical milestone in personalized genomic medicine where genome sequencing becomes an integral part of the clinical setting and will undoubtedly change the practice of medicine. In this article, we elaborate the developments of NGS technologies, and their applications in the oncology clinic. The limitations of NGS and the technical gaps as a diagnostic tool will also be discussed.